Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.incyte.com
Incyte Corporation News Releases
Get the latest updates from Incyte Corporation News Releases directly as they happen.
Follow now 178 followers
Latest posts
Last updated 15 days ago
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
15 days ago
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
29 days ago
TOKYO --(BUSINESS WIRE)--Dec. 22, 2025-- Incyte Biosciences Japan G.K. today announced approval...
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
29 days ago
TOKYO --(BUSINESS WIRE)--Dec. 22, 2025-- Incyte Biosciences Japan G.K. today announced the...
Incyte to Present at Upcoming Investor Conference
about 1 month ago
WILMINGTON, Del. --(BUSINESS WIRE)--Dec. 18, 2025-- Incyte (Nasdaq:INCY) announced today that it...
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
about 1 month ago
Minjuvi ® (tafasitamab) in combination with lenalidomide and rituximab is the first...
Incyte Announces Change to its Board of Directors
about 1 month ago
WILMINGTON, Del. --(BUSINESS WIRE)--Dec. 12, 2025-- Incyte (Nasdaq:INCY) today announced the resignation...
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
about 1 month ago
Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at...
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
about 1 month ago
Rapid and robust reductions in spleen volume and symptoms, and improvements in...
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
about 1 month ago
The Company plans to initiate a Phase 3 program evaluating INCA033989 in...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
about 2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Dec. 3, 2025-- Incyte Corporation (Nasdaq: INCY) announced today...
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
about 2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Dec. 2, 2025-- Incyte (Nasdaq:INCY) today announced its partnership...
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
about 2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Dec. 1, 2025-- Incyte (Nasdaq:INCY) announces the appointment of...